J.Safra Asset Management Corp Buys Shares of 3,111 Amgen Inc. $AMGN

J.Safra Asset Management Corp bought a new position in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, HoldingsChannel reports. The fund bought 3,111 shares of the medical research company’s stock, valued at approximately $1,018,000.

Other large investors also recently made changes to their positions in the company. Anfield Capital Management LLC boosted its position in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC raised its stake in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Board of the Pension Protection Fund acquired a new position in Amgen during the 4th quarter worth $26,000. Manning & Napier Advisors LLC grew its stake in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC acquired a new position in shares of Amgen during the fourth quarter valued at $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s obesity drug MariTide is drawing attention as a potential growth driver, with analysts noting that its less frequent dosing could help the company compete in the fast-growing GLP-1/obesity market. Article Title
• Positive Sentiment: Amgen’s broader growth pipeline is being viewed as a potential offset to patent-related pressure, with some commentary suggesting 2026 could be a “springboard” year if newer drugs gain traction. Article Title
• Neutral Sentiment: Goldman Sachs trimmed its price target on Amgen but kept a Buy rating, signaling some caution on valuation while still seeing upside potential. Article Title
• Neutral Sentiment: Recent market commentary noted that Amgen has underperformed some peers and posted a bigger drop than the broader market, reflecting short-term profit-taking and weaker relative momentum. Article Title
• Negative Sentiment: Market coverage also flagged that Amgen fell more than the market in the latest session, reinforcing concern that investors may be locking in gains after the stock’s strong multi-year run. Article Title

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of recent analyst reports. Truist Financial lifted their price objective on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Wells Fargo & Company raised their target price on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Barclays began coverage on shares of Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective for the company. Finally, Argus lowered their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $354.12.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $337.73 on Thursday. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm has a 50-day moving average of $340.89 and a two-hundred day moving average of $345.53. The company has a market capitalization of $182.28 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.46 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the previous year, the company posted $4.90 EPS. The business’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts expect that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.